Laurus Labs Q2 Results: Profit Zooms Multifold To Rs 195 Crore; Dividend Announced
Laurus Labs' revenue jumped 35% during the September quarter.
Laurus Labs Ltd. reported a massive 883% year-on-year increase in net profit for the September quarter of the financial year ending March 2026.
The consolidated bottom line came in at Rs 194.97 crore, as against Rs 19.84 crore a year earlier, according to its notification to the exchanges on Thursday.
Meanwhile, revenue rose 35.1% year-on-year to Rs 1,653.47 crore in comparison to the previous fiscal's Rs 1,223.70 crore.
The company's margin expanded to 24.4% compared to 14.6% during the same period last year.
The Hyderabad-based drugmaker has also an interim dividend of Rs 0.8 per share. The firm's board has approved the record date of Oct. 31 for determining the eligibility of the shareholders. The dividend amount will be paid on or after Nov. 12, it said.
Laurus Labs Q2 Highlights (Consolidated, YoY)
Revenue up 35.1% to Rs 1,653.47 crore versus Rs 1,223.70 crore.
Net profit up 883% to Rs 194.97 crore versus Rs 19.84 crore.
Ebitda up 126% to Rs 403.26 crore versus Rs 178.33 crore.
Margin at 24.4% versus 14.6%.
The company's stock price was given an 18% upside potential by B&K Securities. Laurus Labs is anticipated to sustain 40% compound annual growth rate in revenue from small molecule CDMO over fiscal 25-28, according to the brokerage firm.
The firm directed the majority of its Rs 4,000-crore capital expenditure towards CDMO capabilities over the past five years.
Shares of Laurus Labs' closed 1.14% higher at Rs 934.40 apiece on the NSE, compared to a 0.09% rise in the benchmark Nifty. The stock has fallen 107.90% in the last 12 months and 55.04% on a year-to-date basis.
Out of 17 analysts tracking the company, eight have a 'buy' rating on the stock, three recommend 'hold' and six suggest 'sell', according to Bloomberg data. The average of 12-month analysts' price target implies a potential downside of 12.4%.
